We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Participants in a Senate hearing Wednesday on drug price manipulation said the best way to stem the practice is to speed competitors to market and consider using compounders. Read More
With the price of opioid rescue drug naloxone nearly quadrupling in Baltimore last year, Baltimore City Health Commissioner Leana Wen called for a federal investigation into the drug, which holds a spot on the World Health Organization’s List of Essential Medicines. Read More
Par Pharmaceutical’s efforts to litigate its way to a generic version of Adderall XR ended with a whimper Nov. 24, after a federal judge barred the company from challenging Shire’s patents. Read More
Teva Pharmaceuticals is trying to divest assets in anticipation of regulatory objections to its purchase of Allergan’s generics division, according to a corporate filing. Read More
An international aid group has negotiated a multi-year licensing agreement with Bristol-Myers Squibb to produce generic hepatitis C medicines in many developing nations. Read More
The nation’s largest pharmacy benefits manager is throwing its support behind a cheaper alternative to Turing Pharmaceuticals’ expensive toxoplasmosis/HIV treatment, threatening its monopoly on the market. Read More
In a win for branded drugmakers, President Barack Obama signed into law a bill extending the exclusivity periods for many new drugs and biologics. The measure — H.R. 639, referred to as the “Improving Regulatory Transparency for New Medical Therapies Act” — was signed into law Nov. 25, congressional records show. Read More